Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.
Fiche publication
Date publication
mars 2018
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M
Lien Pubmed
Résumé
In clinical practice, treatment sequences of biologicals are applied for active fistulising Crohn's disease, however underlying health economic analyses are lacking.
Mots clés
Cost-effectiveness, adalimumab, biosimilar, biosimilar-infliximab, fistulising Crohn’s disease, infliximab, vedolizumab
Référence
United European Gastroenterol J. 2018 Mar;6(2):310-321